ALK(SZ:002940) Xin Lang Cai Jing·2025-09-04 06:34Group 1 - The stock price of Anglikon Pharmaceuticals dropped by 5.06% to 43.49 CNY per share, with a trading volume of 363 million CNY and a turnover rate of 4.37%, resulting in a total market capitalization of 8.773 billion CNY [1] - Anglikon Pharmaceuticals, established on December 30, 2001, and listed on October 23, 2018, is primarily engaged in the research, production, and sales of chemical raw materials and formulations [1] - The revenue composition of Anglikon Pharmaceuticals includes formulations at 43.46%, raw materials at 39.82%, specialty intermediates at 12.44%, other products at 3.72%, and pharmaceutical excipients at 0.56% [1] Group 2 - In the second quarter, Invesco Great Wall Fund held 48,000 shares of Anglikon, representing 4.95% of the fund's net value, making it the eighth largest holding [2] - The Invesco Great Wall Medical Industry Stock A fund, established on January 24, 2025, has a latest scale of 15.9413 million CNY and has achieved a return of 72.54% since inception [2] - The fund manager, Qiao Haiying, has a tenure of 10 years and 361 days, with total assets under management of 327 million CNY, achieving a best return of 147.43% and a worst return of -11.7% during the tenure [2]